Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06280534
Other study ID # XT1061-2022-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 18, 2023
Est. completion date March 31, 2024

Study information

Verified date January 2024
Source Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Contact Ding Yanhua, ??
Phone 18743062721
Email 1023307193@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.


Description:

This trial is a randomized, double-blind, dose-escalation, placebo-controlled, single-center clinical study designed to evaluate the safety, tolerability, pharmacokinetic profile and metabolic conversion of XT1061 in healthy subjects with single and multiple administrations, as well as a study of the effect of food on pharmacokinetics.


Recruitment information / eligibility

Status Recruiting
Enrollment 128
Est. completion date March 31, 2024
Est. primary completion date February 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Subjects voluntarily sign the informed consent before the trial, and fully understand the content, process and possible adverse effects of the trial; 2. They are able to complete the study according to the requirements of the trial protocol; 3. Subjects (including partners) are willing to have no pregnancy plan and voluntarily use effective contraceptive measures within 6 months from screening to the last dose of study drug; 4. Male and female subjects between the ages of 18 and 65 (including borderline values); 5. Male subjects weighing not less than 50 kg and female subjects weighing not less than 45 kg. Body mass index (BMI) = weight (kg)/height 2 (m2), BMI within the range of 18-28 kg/m2 (including the threshold value); 6. Physical examination and vital signs are normal or abnormal without clinical significance. Exclusion Criteria: 1. Allergy (multiple drug and food allergies); 2. Those who smoked more than 5 cigarettes per day in the 3 months prior to the test; 3. History of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); 4. Blood donation or significant blood loss (> 450 mL) within three months prior to taking study drug; 5. taking any prescription drug, over-the-counter drug, any vitamin product, herbal remedy, or alcohol within 14 days prior to taking study drug; 6. have taken a special diet (e.g., grapefruit, mango, dragon fruit, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides), or have had strenuous physical activity, or any other factor that affects the absorption, distribution, metabolism, or excretion of the drug within 2 weeks prior to administration of the study drug; 7. Those who have recently made significant changes in their dietary or exercise habits; 8. have taken the study drug, or participated in a clinical trial of the drug within three months prior to taking the study drug; 9. have dysphagia or a history of any gastrointestinal disorder that interferes with the absorption of the drug within 6 months prior to the trial; 10. have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastroduodenal ulcers 11. clinically significant ECG abnormalities; QTcF >470ms (QTcF=QT/(RR)^0.33); and 12. Female subjects who are breastfeeding or recently preparing for pregnancy or have a positive serum pregnancy result during the screening period or during the course of the trial; 13. Abnormal and clinically significant clinical laboratory tests, or other clinical findings within the 12 months prior to screening that indicate clinically significant disease of the following (including, but not limited to, gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disease); 14. Positive screening for any of the Hepatitis B Surface Antigen, Hepatitis C Antibody/Hepatitis C Core Antigen, HIV Antigen/Antibody, or Syphilis Spirochete Antibody; 15. Acute illness or concomitant medication from the screening phase until study drug administration; 16. ingestion of chocolate, any caffeinated or xanthine-containing food or beverage 24 hours prior to study drug administration; 17. A positive urine drug screen or a history of substance abuse or drug use within the past five years; 18. serum creatinine clearance = 70 mL/min [formula: Ccr: (140 - age) × body weight (kg) / (0.818 × Scr) (µmol/L), female × 0.85]. 19. Those who have special dietary requirements and cannot eat the entire test meal. Or those who did not agree to comply with the drinking arrangements and postural restrictions during the trial; 20. Subjects who, in the opinion of the investigator, have other factors that make them unsuitable for participation in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Test drug XT1061 capsules and placebo,Single dose group
Eight people took capsules of the test drug XT1061 and two people took a placebo.
Test drug XT1061 capsules and placebo,Multiple dosing group
D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
Test drug XT1061 capsules and placebo,Food Impact Group
Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.

Locations

Country Name City State
China The First Hospital of Jilin University Jilin Changchun

Sponsors (1)

Lead Sponsor Collaborator
Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment-related adverse events Number of participants who experienced treatment-related adverse events as assessed by CTCAE v5.0. Day 7
Primary Cmax Cmax Day 4
Primary Tmax Tmax Day 4
Primary t1/2 t1/2 Day 4
Primary AUC AUC Day 4
Primary CL/F CL/F Day 4
Primary Vz/F Vz/F Day 4
Primary CLr/F CLr/F Day 4
Secondary Ae0-72 h Ae0-72 h Day 4
Secondary Fe0-72 h Fe0-72 h Day 4
Secondary bioavailability geometric mean value ratio Day 4
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A